Skip to main content
Message Font: Serif | Sans-Serif
No. of Recommendations: 1
Good writeup on the TFFP technology and potential markets and partnering opportunities:

All told, TFF is currently working on material transfer agreements and statements of work with 20 different companies on vaccines, biologics, new chemical entities and botanicals, including UNION Therapeutics (niclosamide), the University of Georgia (flu vaccine), and the U.S. Amy (antiviral monoclonal antibodies and antivirals). That’s in addition to the company’s three internal programs; a dry powder formulation of voriconazole to treat Invasive Pulmonary Aspergillosis, the immunosuppressive drug tacrolimus used in solid organ transplants, and an inhaled dry powder drug combination intended to treat COPD and asthma. Those programs are operating under the 505(b)(2) regulatory pathway intended for molecules that have been previously approved by the FDA as safe and effective.

Market cap is now about 400 million or 2x the the $210 million in milestone payments contracted for their first drug.

I have a full position now considering nibbling to go a bit overweight. It seems to me things are moving much faster than a typical pharmaceutical company since they are working with previously approved molecules.

Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.